

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/562,261
Filing Date	July 6, 2006
First Named Inventor	Francis J. Michon
Art Unit	1645
Examiner Name	Nina Archie
Attorney Docket Number	00518-105087

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		4,727,136	02-23-1988	Jennings et al.	
		5,097,020	03-17-1992	Anderson et al.	
		5,153,312	10-06-1992	Porro	
		5,425,946	06-20-1995	Tai et al.	
		5,785,973	07-28-1998	Bixler et al.	
		6,350,861	02-26-2002	Co et al.	
		2006/0035284	02-16-2006	Granoff et al.	
		2007/0154492	07-05-2007	Michon et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ - Number ⁵ - Kind Code ⁶ (if known)				
		EP 0 238 739	09-30-1987	Swiss Serum and Vaccine Institute		
		EP 0 477 508	07-12-1995	American Cyanamid Company		
		EP 0 497 525	08-05-1992	Merck & Co., Inc.		
		WO 99/32653	07-01-1999	North American Vaccine, Inc.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/562,261
Filing Date	July 6, 2006
First Named Inventor	Francis J. Michon
Art Unit	1645
Examiner Name	Nina Archie
Attorney Docket Number	00518-105087

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Jennings et al., "Conjugation of Meningococcal Lipopolysaccharide R-Type Oligosaccharides to Tetanus Toxoid as Route to a Potential Vaccine Against Group B Neisseria Meningitidis," Infection and Immunity, 43(1), pp. 407-412, January 1984	
		Jennings et al., Induction of Meningococcal Group B Polysaccharide-Specific IgG antibodies in mice by using an N-propionylated B Polysaccharide-Tetanus Toxoid Conjugate Vaccine, J. Immunol., 137:1708-1713, 1986	
		Michon et al., "Structure Activity Studies on Group C Meningococcal Polysaccharide-Protein Conjugate Vaccines: Effect of O-Acetylation on the Nature of the Protective Epitope," Dev. Biol., 103, pp. 151-160, 2000	
		Millipore Pellicon 2 Microfiltration Modules, pp. 1-4, July 26, 2010	
		Moore et al., "Eptiope Specificities of the Group Y and W-135 Polysaccharides of Neisseria Meningitidis," Clinical and Vaccine Immunology, 14(10), pp. 1311-1317, October 2007	
		Pacletti et al., "Group B Streptococcus Type II Polysaccharide-Tetanus Toxoid Conjugate Vaccine," Infection and Immunity, 60(10), pp. 4009-4014, October 1992	
		Wessels et al., "Isolation and Characterization of Type IV Group B Streptococcus Capsular Polysaccharide," Infection and Immunity, 57(4), pp. 1089-1094, April 1989	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.